Bioequivalence Study for Fluticasone Propionate 250 mcg/Salmeterol Xinafoate 50 mcg Inhalation Powder in Healthy Volunteers

NCT05982990 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

34

Enrollment

INDUSTRY

Sponsor class

Conditions

Bioequivalence

Interventions

DRUG: Fluticasone propionate 250 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals
DRUG: ADVAIR DISKUS® 250/50

Sponsor

Respirent Pharmaceuticals Co Ltd.

Collaborators

[object Object]